Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellowship, Hematology / Oncology, Duke University School of Medicine 2010 - 2013
  • Residency, General Internal Medicine, Duke University School of Medicine 2006 - 2009
  • M.D., Duke University 2006
• 

  Previous Appointments & Affiliations

  • Assistant Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2017 - 2020
  • Medical Instructor in the Department of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2013 - 2017
  • Medical Instructor in the Department of Medicine, Medicine, General Internal Medicine, Medicine 2009 - 2010
• 

  Leadership & Clinical Positions at Duke

  • Co-director Duke Cancer Institute Molecular Tumor Board
• Research
• 

  Selected Grants

  • An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER-WaM) awarded by Cellectar Biosciences, Inc. 2023 - 2028
  • PHASE III RANDOMIZED, OPEN-LABEL,MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN COMPARISON TO RITUXIMAB IN COMBINATION WITH LENALIDOMIDE IN PATIENTS WITH FOLLICULAR LYMPHOMA AFTER AT LEAST ONE awarded by Genentech, Inc. 2022 - 2027
  • A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF GLOFITAMAB IN COMBINATION WITH GEMCITABINE awarded by Genentech, Inc. 2021 - 2026
  • LOXO Oncology study awarded by Loxo Oncology, Inc. 2020 - 2025
  • A multicenter retrospective non-interventional follow-up study in patients with sickle cell pain crisis who previously participated in the SUSTAIN trial in the United States awarded by Novartis Pharmaceuticals Corporation 2020 - 2025
  • ATTCK-20-03 awarded by Unum Therapeutics Inc. 2020 - 2025
  • Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Roituximab and Chemotherapy awarded by Atara Biotherapeutics, Inc. 2020 - 2025
  • LYMRIT 37-01 awarded by Nordic Nanovector ASA 2019 - 2024
  • A PHASE I/II TRIAL OF MOSUNETUZUMAB (BTCT4465A) AS CONSOLIDATION THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FOLLOWING FIRST-LINE IMMUNOCHEMOTHERAPY AND AS THERAPY IN PATIENTS WITH PREVIOUS awarded by Genentech, Inc. 2019 - 2024
  • A Phase 2a Open-label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractor awarded by Molecular Templates, Inc. 2019 - 2023
  • BeiGene BGB-3111-212 An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma awarded by BeiGene, Ltd 2018 - 2023
  • A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB-50465, a PI3K8 Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203) awarded by Incyte Corporation 2018 - 2023
  • Advancing Cancer Care in the Rural Southeast: Enhancing Precision Medicine and Institutional Collaboration in Community Cancer Centers awarded by V Foundation for Cancer Research 2021 - 2023
  • Partnership to Support the Duke Molecular Tumor Board Program awarded by Bayer Healthcare Pharmaceuticals Inc 2020 - 2022
  • A Single Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphome (FL) awarded by The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership 2014 - 2022
  • Phase 3 Randomized Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) R-Chop Chemotherapy (R2-Chop) versus Placebo plus R-Chop Chemotherapy in Subjects with previously untreated Lymphoma awarded by Celgene Corporation 2015 - 2022
  • Advancing Cancer Care in the Rural Southeast: Delivering Novel Therapies In Our Community Cancer Centers awarded by V Foundation for Cancer Research 2019 - 2021
  • A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma awarded by Janssen Research & Development, LLC 2013 - 2021
  • Long Term Follow-Up Study of Clinical Study Subjects Treated with ACTR087, Autologous T Cells Expressing Antibody-Coupled T-Cell Receptors awarded by Unum Therapeutics Inc. 2017 - 2021
  • Phase I Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Couple T-Cell Receptors (CD16V-41BB-CD35), in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma awarded by Unum Therapeutics Inc. 2016 - 2021
  • Denovo DB102-02 A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1¿ awarded by Denovo Biopharma, LLC 2018 - 2021
  • A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI13K Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205) awarded by Incyte Corporation 2018 - 2020
  • Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab vedotin versus Brentuximab vedotin alone Participatns with Relasped Refractory or Ineligible for Autologous Stem Cell Transplant awarded by The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership 2018 - 2020
  • Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma awarded by Pharmacyclics, Inc. 2018 - 2020
  • A Phase 2, Open-Label, 2-C Cohort Study of INCB050465, A P13K@ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204) awarded by Incyte Corporation 2017 - 2020
  • Phase 1 Trial of Panobinostat + Ruxolitnib for Relapsed/Refactory Diffused Large B Cell Lymphoma (DLBCL) awarded by Lymphoma Research Foundation of America 2016 - 2019
  • A Phase 1/2 Study Evaluating Brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma awarded by Seattle Genetics, Inc 2016 - 2019
  • A Randomized Open Label Phase 2 Study of Denintuzumab mafodotin (SGN -CD19A) awarded by Seattle Genetics, Inc 2016 - 2019
  • Novel combinations to overcome resistance to histone deacetylase inhibitors in lymphoma awarded by Leukemia & Lymphoma Society 2015 - 2016
• 

  External Relationships

  • ADC therapeutics
  • BeiGene
  • E.R. Squibb & Sons (Bristol Myers Squibb)
  • Epizyme
  • Incyte
  • Kite pharmaceuticals (Gilead)
  • Novartis
  • Roche/Genentech
  • Takeda
• Publications & Artistic Works
• 

  Selected Publications

  • Books

    • Ginsburg, G. S., H. F. Willard, J. H. Strickler, and M. S. McKinney. Genomic and Precision Medicine: Oncology, Third Edition, 2022. https://doi.org/10.1016/C2015-0-06901-5.
       Full Text
    • Strickler, J. H., and M. S. McKinney. Preface, 2022. https://doi.org/10.1016/B978-0-12-800684-9.00007-1.
       Full Text

  • Academic Articles

    • Lin, Chenyu, Ahmed Galal, David Rizzieri, Sant Chawla, Seung T. Lee, Angela Georgy, Kristina Dabovic, Thomas Strack, and Matthew McKinney. “Combinatorial Efficacy and Toxicity of an Engineered Toxin Body MT-3724 with Gemcitabine and Oxaliplatin in Relapsed or Refractory Diffuse Large B Cell Lymphoma.” Cancer Invest, January 31, 2023, 1–10. https://doi.org/10.1080/07357907.2022.2162073.
       Full Text  Link to Item
    • Siddiqi, Tanya, Steven Coutre, Matthew McKinney, Paul M. Barr, Kerry Rogers, Ahmad Mokatrin, Rudy Valentino, et al. “Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.” Leuk Lymphoma 63, no. 7 (July 2022): 1580–88. https://doi.org/10.1080/10428194.2022.2038372.
       Full Text  Link to Item
    • Fairchild, Andrew, Chad M. McCall, Taofik Oyekunle, Donna Niedzwiecki, Colin Champ, Matthew McKinney, and Chris R. Kelsey. “Primary Mediastinal (Thymic) Large B-Cell Lymphoma: Fidelity of Diagnosis Using WHO Criteria.” Clin Lymphoma Myeloma Leuk 21, no. 5 (May 2021): e464–69. https://doi.org/10.1016/j.clml.2020.12.015.
       Full Text  Link to Item
    • Green, Michelle F., Jonathan L. Bell, Christopher B. Hubbard, Shannon J. McCall, Matthew S. McKinney, Jinny E. Riedel, Carolyn S. Menendez, James L. Abbruzzese, John H. Strickler, and Michael B. Datto. “Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University Experience.” Jco Precis Oncol 5 (2021). https://doi.org/10.1200/PO.21.00030.
       Full Text  Link to Item
    • Watson, Catherine H., Gloria Broadwater, Janice Wong, Daniel Spinosa, Mary Katherine Montes de Oca, Michael Datto, Michelle Green, et al. “Results and Clinical Utilization of Foundation Medicine Molecular Tumor Profiling in Uterine and Ovarian Cancers.” Target Oncol 16, no. 1 (January 2021): 109–18. https://doi.org/10.1007/s11523-020-00785-z.
       Full Text  Link to Item
    • Hoppe, Richard T., Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Philippe Armand, Celeste M. Bello, Cecil M. Benitez, et al. “Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 18, no. 6 (June 2020): 755–81. https://doi.org/10.6004/jnccn.2020.0026.
       Full Text  Link to Item
    • Li, Xiang, Rachel Kositsky, Anupama Reddy, Cassandra Love, Kikkeri Naresh, Jean L. Koff, Ilja Nystrand, et al. “Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma.” Blood 134, no. Supplement_1 (November 13, 2019): 19. https://doi.org/10.1182/blood-2019-130255.
       Full Text  Link to Item
    • McKinney, M. S. “New horizons in the treatment and management of Lymphoma: Novel therapies for improved patient outcomes.” Journal of Managed Care Medicine 22, no. 2 (January 1, 2019): 73–78.
    • Strickler, John H., Jonathan M. Loree, Leanne G. Ahronian, Aparna R. Parikh, Donna Niedzwiecki, Allan Andresson Lima Pereira, Matthew McKinney, et al. “Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer.” Cancer Discov 8, no. 2 (February 2018): 164–73. https://doi.org/10.1158/2159-8290.CD-17-1009.
       Full Text  Link to Item
    • Moffitt, Andrea B., Sarah L. Ondrejka, Matthew McKinney, Rachel E. Rempel, John R. Goodlad, Chun Huat Teh, Sirpa Leppa, et al. “Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2.” J Exp Med 214, no. 5 (May 1, 2017): 1371–86. https://doi.org/10.1084/jem.20160894.
       Full Text  Link to Item
    • McKinney, Matthew, Andrea B. Moffitt, Philippe Gaulard, Marion Travert, Laurence De Leval, Alina Nicolae, Mark Raffeld, et al. “The Genetic Basis of Hepatosplenic T-cell Lymphoma.” Cancer Discov 7, no. 4 (April 2017): 369–79. https://doi.org/10.1158/2159-8290.CD-16-0330.
       Full Text  Link to Item
    • Healy, Jane A., Adrienne Nugent, Rachel E. Rempel, Andrea B. Moffitt, Nicholas S. Davis, Xiaoyu Jiang, Jennifer R. Shingleton, et al. “GNA13 loss in germinal center B cells leads to impaired apoptosis and promotes lymphoma in vivo.” Blood 127, no. 22 (June 2, 2016): 2723–31. https://doi.org/10.1182/blood-2015-07-659938.
       Full Text  Link to Item
    • Papalas, John A., Matthew S. McKinney, Evan Kulbacki, Sandeep S. Dave, and Endi Wang. “Merkel cell carcinoma with partial B-cell blastic immunophenotype: a potential mimic of cutaneous richter transformation in a patient with chronic lymphocytic lymphoma.” Am J Dermatopathol 36, no. 2 (February 2014): 148–52. https://doi.org/10.1097/DAD.0b013e31829ed784.
       Full Text  Link to Item
    • Walsh, Katherine, Matthew S. McKinney, Cassandra Love, Qingquan Liu, Alice Fan, Amee Patel, Jason Smith, Anne Beaven, Dereje D. Jima, and Sandeep S. Dave. “PAK1 mediates resistance to PI3K inhibition in lymphomas.” Clin Cancer Res 19, no. 5 (March 1, 2013): 1106–15. https://doi.org/10.1158/1078-0432.CCR-12-1060.
       Full Text  Link to Item
    • Love, Cassandra, Zhen Sun, Dereje Jima, Guojie Li, Jenny Zhang, Rodney Miles, Kristy L. Richards, et al. “The genetic landscape of mutations in Burkitt lymphoma.” Nat Genet 44, no. 12 (December 2012): 1321–25. https://doi.org/10.1038/ng.2468.
       Full Text  Link to Item
    • Morse, M. A., A. Hobeika, D. Serra, K. Aird, M. McKinney, A. Aldrich, T. Clay, et al. “Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function.” Cancer Gene Ther 19, no. 1 (January 2012): 30–37. https://doi.org/10.1038/cgt.2011.63.
       Full Text  Link to Item
    • McKinney, Matthew, and Murat O. Arcasoy. “Erythropoietin for oncology supportive care.” Exp Cell Res 317, no. 9 (May 15, 2011): 1246–54. https://doi.org/10.1016/j.yexcr.2011.03.003.
       Full Text  Link to Item
    • Osada, Takuya, Christopher Y. Woo, Matthew McKinney, Xiao Yi Yang, Gangjun Lei, Heather G. Labreche, Zachary C. Hartman, et al. “Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.” Clin Cancer Res 15, no. 8 (April 15, 2009): 2789–96. https://doi.org/10.1158/1078-0432.CCR-08-2589.
       Full Text  Link to Item
    • McKinney, M., and M. A. Morse. “Advances in immunotherapy for colorectal malignancies.” Current Colorectal Cancer Reports 4, no. 4 (October 1, 2008): 177–83. https://doi.org/10.1007/s11888-008-0029-7.
       Full Text

  • Book Sections

    • McKinney, M. S., and J. H. Strickler. “Introduction and overview of cancer precision medicine.” In Genomic and Precision Medicine: Oncology, Third Edition, 1–11, 2022. https://doi.org/10.1016/B978-0-12-800684-9.00008-3.
       Full Text
    • Jauhari, S., and M. McKinney. “Hepatosplenic T-cell lymphoma.” In Novel Therapeutics for Rare Lymphomas, 209–20, 2019. https://doi.org/10.1007/978-3-030-25610-4_13.
       Full Text
    • McKinney, M. S., and S. S. Dave. “Origin of Non-Hodgkin Lymphoma.” In Hematology: Basic Principles and Practice, 1230–43, 2017. https://doi.org/10.1016/B978-0-323-35762-3.00076-7.
       Full Text
    • McKinney, M. S., and S. S. Dave. “Origin of Non-Hodgkin Lymphoma.” In Hematology Basic Principles and Practice, edited by R. Hoffman, E. J. Benz, L. E. Silberstein, H. E. Heslop, J. I. Weitz, J. Anastasi, M. E. Salama, and S. A. Abutalib. Elsevier Health Sciences, 2013.
    • McKinney, M. S., and J. Crawford. “Erythropoiesis-stimulating agents in older adults with cancer.” In Practical Geriatric Oncology, 338–50, 2010. https://doi.org/10.1017/CBO9780511763182.024.
       Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.